{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:43:33Z","timestamp":1791085413905,"version":"4.1.0"},"reference-count":37,"publisher":"Rockefeller University Press","issue":"1","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:p>One of the greatest thrills a biomedical researcher may experience is seeing the product of many years of dedicated effort finally make its way to the patient. As a team, we have worked for the past eight years to discover a drug that could treat a devastating childhood neuromuscular disease, spinal muscular atrophy (SMA). Here, we describe the journey that has led to a promising drug based on the biology underlying the disease.<\/jats:p>","DOI":"10.1083\/jcb.201207087","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T17:45:17Z","timestamp":1349113517000},"page":"21-25","update-policy":"https:\/\/doi.org\/10.1083\/jcb.crossmarkpolicy","source":"Crossref","is-referenced-by-count":164,"title":["Antisense-based therapy for the treatment of spinal muscular atrophy"],"prefix":"10.1083","volume":"199","author":[{"given":"Frank","family":"Rigo","sequence":"first","affiliation":[{"name":"Isis Pharmaceuticals, Carlsbad, CA 92010 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Hua","sequence":"additional","affiliation":[{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian R.","family":"Krainer","sequence":"additional","affiliation":[{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Frank","family":"Bennett","sequence":"additional","affiliation":[{"name":"Isis Pharmaceuticals, Carlsbad, CA 92010 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2012,10,1]]},"reference":[{"key":"2023072306285351300_bib1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpeds.2009.01.071","article-title":"Vascular perfusion abnormalities in infants with spinal muscular atrophy","volume":"155","author":"Araujo","year":"2009","journal-title":"J. Pediatr."},{"key":"2023072306285351300_bib2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2023072306285351300_bib3","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","article-title":"Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery","volume":"19","author":"Bevan","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2023072306285351300_bib4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.neuroscience.2004.11.038","article-title":"Spinal distribution and metabolism of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats","volume":"131","author":"Butler","year":"2005","journal-title":"Neuroscience."},{"key":"2023072306285351300_bib5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat. Genet."},{"key":"2023072306285351300_bib6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nsb887","article-title":"Correction of disease-associated exon skipping by synthetic exon-specific activators","volume":"10","author":"Cartegni","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"2023072306285351300_bib7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol. Dis."},{"key":"2023072306285351300_bib8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00431-004-1437-6","article-title":"Spinal muscle atrophy type 1 (Werdnig-Hoffman disease) with complex cardiac malformation","volume":"163","author":"El-Matary","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"2023072306285351300_bib9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1533-2500.2006.00059.x","article-title":"Drug delivery systems","volume":"6","author":"Erdine","year":"2006","journal-title":"Pain Pract."},{"key":"2023072306285351300_bib10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"2023072306285351300_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2023072306285351300_bib12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1124\/dmd.31.11.1419","article-title":"Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2\u2032-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species","volume":"31","author":"Geary","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"2023072306285351300_bib13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.bcp.2009.04.013","article-title":"Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2\u2032-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN","volume":"78","author":"Geary","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"2023072306285351300_bib14","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/hmg\/ddq330","article-title":"Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice","volume":"19","author":"Heier","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2023072306285351300_bib15","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.1073\/pnas.160181697","article-title":"Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)","volume":"97","author":"Hofmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072306285351300_bib16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat. Genet."},{"key":"2023072306285351300_bib17","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","article-title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon","volume":"5","author":"Hua","year":"2007","journal-title":"PLoS Biol."},{"key":"2023072306285351300_bib18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"2023072306285351300_bib19","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"2023072306285351300_bib20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature."},{"key":"2023072306285351300_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023072306285351300_bib22","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"2023072306285351300_bib23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron."},{"key":"2023072306285351300_bib24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"issue":"R1","key":"2023072306285351300_bib25","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1093\/hmg\/ddq147","article-title":"Spinal muscular atrophy: mechanisms and therapeutic strategies","volume":"19","author":"Lorson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2023072306285351300_bib26","doi-asserted-by":"crossref","DOI":"10.2119\/molmed.2012.00056","article-title":"IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of SMA","author":"Murdocca","year":"2012","journal-title":"Mol. Med."},{"key":"2023072306285351300_bib27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2023072306285351300_bib28","doi-asserted-by":"crossref","first-page":"72r18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucelotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2023072306285351300_bib29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1042-3680(03)00016-0","article-title":"Intrathecal medication delivery","volume":"14","author":"Penn","year":"2003","journal-title":"Neurosurg. Clin. N. Am."},{"key":"2023072306285351300_bib30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nchembio.939","article-title":"Modulation of gene expression by antisense oligonucleotide directed recruitment of specific proteins to RNA","volume":"8","author":"Rigo","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"2023072306285351300_bib31","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1093\/hmg\/ddq329","article-title":"Cardiac defects contribute to the pathology of spinal muscular atrophy models","volume":"19","author":"Shababi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2023072306285351300_bib32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4161\/rna.8.4.16224","article-title":"Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model","volume":"8","author":"Singh","year":"2011","journal-title":"RNA Biol."},{"key":"2023072306285351300_bib33","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"2023072306285351300_bib34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4161\/rna.6.3.8723","article-title":"A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy","volume":"6","author":"Singh","year":"2009","journal-title":"RNA Biol."},{"key":"2023072306285351300_bib35","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2023072306285351300_bib36","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"2023072306285351300_bib37","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0002-9440(10)63428-1","article-title":"Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload","volume":"165","author":"Vitte","year":"2004","journal-title":"Am. J. Pathol."}],"container-title":["Journal of Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jcb\/article-pdf\/199\/1\/21\/1582972\/jcb_201207087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jcb\/article-pdf\/199\/1\/21\/1582972\/jcb_201207087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T21:14:36Z","timestamp":1744233276000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jcb\/article\/199\/1\/21\/37152\/Antisense-based-therapy-for-the-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.1083\/jcb.201207087","relation":{},"ISSN":["1540-8140","0021-9525"],"issn-type":[{"value":"1540-8140","type":"electronic"},{"value":"0021-9525","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,1]]}}}